Inhibitex is a clinical-stage biopharmaceutical company dedicated to the development of innovative products that can treat or prevent serious infections. We are applying our expertise in the development of a portfolio of high-value, differentiated infectious disease therapies, each of which has the potential to significantly improve existing standards of care. Our pipeline addresses major viral and bacterial infections, including herpes zoster (shingles), HCV, and S. aureus infections.